Organization
CSPC Pharmaceutical Group Limited
3 abstracts
Abstract
Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.Org: Hebei University Affiliated Hospital, Affiliated Cancer Hospital of Harbin Medical University, Jiamusi Cancer and Tuberculosis Hospital, Phase I Clinical Trials Center, CSPC Pharmaceutical Group Limited,
Abstract
First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.Org: Fujian Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, The Affiliated Tumor Hospital of Harbin Medical University, Medical Oncology Department of Gastrointestinal Cancer, Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China,
Abstract
ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study.Org: Peking University People's Hospital, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Department of Orthopedic, The First Affiliated Hospital of Fujian Medical University, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,